Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 89

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 89
---
 |         3,750 |     | $        | 10.00 |     | 09/30/2034 |
| Kristen Pierce, Ph.D.,         
 Chief Development Officer      |     | 10/01/2024 |     | 10/01/2024   |     |         1,784 |     |           875 |     | $        | 10.00 |     | 09/30/2034 |

50

Employee Benefits and Equity Incentive Compensation Plan Equity Incentive Compensation We believe it is important to maintain a strong link between executive incentives and the creation of stockholder value. We believe performance and equity -basedcompensation for our executives to be an important component of maximizing stockholder value while, at the same time, attracting, motivating and retaining high -qualityexecutives. Upon consummation of the Business Combination, we assumed options issued pursuant to the CERo Therapeutics, Inc. 2016 Equity Incentive Plan, as amended (the “2016 Plan”), and we currently maintain the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and the CERo Therapeutics Holdings, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”). As of December 31, 2023, the 2016 Plan had options outstanding to purchase a total of 7,825shares of common stock for a weighted average exercise price of $28.00 per share. On February 14, 2024, upon consummation of the Business Combination, these options were assumed by us and converted into options to purchase shares in CERo at a conversion rate of 0.064452 underlying shares per legacy share and a strike price calculated as the legacy strike price divided by 0.064452. This resulted in the issuance of options to purchase 504shares of common stock at a weighted average price of $436.00. As of October 1, 2024, the board of directors approved option awards to the executive officers for 2024, as set forth below:

| Name and Position                                               |     |   Stock 
 Options |
| Chris Ehrlich, Chief Executive Officer and Chairman(1)          |     |  25,500 |
| Andrew “Al” Kucharchuk, Chief Financial Officer                 |     |   5,000 |
| Kristen Pierce, Ph.D., Chief Development Officer                |